Genfit S.A. (XUPB.MU)
Chart Events
Performance Outlook
| Previous Close | 3.8600 |
| Open | 3.8600 |
| Bid | 3.8600 x 0 |
| Ask | 4.0800 x 0 |
| Day's Range | 3.8600 - 3.8600 |
| 52 Week Range | 3.0000 - 4.6400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 192.288M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | 4.65 |
| EPS (TTM) | 0.8300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for XUPB.MU
Related Research
- GlobeNewswire
GENFIT Announces 2023 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial
- GlobeNewswire
GENFIT to Participate in Upcoming Investor Conferences
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences. Conference Details (non-exhaustive list): Corporate Access Events during the 41st JPMorgan Healthcare ConferenceDate: January 8 – 12, 202
- GlobeNewswire
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of actionA regular stream of new clinical data expected over the next few years across the spectrum of development stages (Phase 1, Phase 2, Phase 3)Aggregated global market size potential >$15bn1, distributed among acute on-chronic liver failure (ACLF) w
